DB102

April 9, 2018

First Patient Dosed in Phase 3 Trial of Denovo’s DB102 Plus Chemo for High-risk DLBCL

News

A pivotal Phase 3 trial evaluating Denovo Biopharma‘s investigational therapy DB102 (enzastaurin) as an add-on to standard chemotherapy for high-risk diffuse large B-cell lymphoma (DLBCL) has started dosing patients. The ENGINE ... Read more

October 27, 2017October 27, 2017

FDA Clears Way for Denovo to Launch Phase 3 Trial of DB102 for DLBCL Patients in US

News

The U.S. Food and Drug Administration (FDA) has given Denovo Biopharma the green light to advance its investigational drug DB102 into a Phase 3 clinical trial for diffuse large B-cell lymphoma ... Read more

February 20, 2017October 26, 2017

Denovo Plans Phase 3 Trial of Its DB102 Therapy for Subset of Lymphoma Patients

News

Denovo Biopharma will start a global Phase 3 trial this year to assess its PKCβ inhibitor, DB102, as a first-line therapy for a subset of patients with diffuse large B-cell lymphoma ... Read more